Plan of the Day Radiotherapy for Locally Advanced Cervical Cancer
Compares a plan-of-the-day radiation approach with standard radiation in adults with cervical cancer.
Plain-language title generated from the registry record
Registry title: Plan of the Day Radiotherapy
Key facts
- Where
- Oslo, NorwaySee the site
Where in Norway
- Oslo University HospitalOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT05634681
- Record updated
- 2 December 2022
- Original description
The study objectives are to improve the treatment of LACC patients and to increase knowledge of the potential benefit of the plan-of-the-day concept on side effects during and after radiotherapy.Read full original descriptionShow less
Plan-of-the-day Radiotherapy for Patients With Locally Advanced Cervical Cancer - a Prospective Randomized Controlled Trial (the POD-protocol)
The study objectives are to improve the treatment of LACC patients and to increase knowledge of the potential benefit of the plan-of-the-day concept on side effects during and after radiotherapy.
Inclusion: Histologically confirmed cervical cancer eligible for definitve radiochemotherapy; FIGO stage IB1-IVa; Over 18 years; Speaks and understands Norwegian or English; ECOG 0-2; Histology: Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma; Ability to understand and fill in patient questionnaires, and willing to sign a written informed consent; Large movers (LM), fundus movement ≥2,5 cm.
Exclusion: Evidence of distant metastasis. Suspicious paraaortic lymphnodes below the renal vessels is allowed if they are covered by the radiation field; Patients with previous surgery for their cervical cancer; Prior radiotherapy to the pelvis; Patients who are pregnant or breastfeeding is excluded due to risk of teratogenic and abortifacient effects of radiotherapy and cisplatin, and the potential risk of adverse effect of nursing infants; Uncontrolled intercurrent somatic illness; Psychiatric illness /social situations limiting study compliance; Patients under current treatment for other invasive s except non-melanoma skin cancers; Patients with inflammatory bowel disease; Nephrostomy.